艾德生物(300685) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥246,782,770.58, representing a 22.78% increase year-over-year, and total revenue for the year-to-date reached ¥645,735,626.15, up 33.41% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2021 was ¥65,233,520.52, a 43.92% increase year-over-year, while the year-to-date net profit reached ¥176,555,722.68, up 39.98%[6] - The basic earnings per share for Q3 2021 was ¥0.29, reflecting a 38.10% increase compared to the same period last year, with diluted earnings per share also at ¥0.29[6] - Total operating revenue for the third quarter reached ¥645,735,626.15, an increase of 33.4% compared to ¥484,020,471.55 in the same period last year[36] - Net profit for the period was ¥176,496,035.76, representing a 40% increase from ¥126,130,439.48 in the previous year[36] - Total comprehensive income attributable to the parent company was approximately CNY 176.07 million, an increase from CNY 125.94 million in the previous period, representing a growth of 40%[40] - Basic and diluted earnings per share increased to CNY 0.79 from CNY 0.57, reflecting a growth of 38.6%[40] Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥1,427,766,629.51, a 10.43% increase from the end of the previous year[6] - Total assets increased to ¥1,427,766,629.51, up from ¥1,292,897,713.11, marking a growth of 10.4%[34] - Total liabilities decreased to ¥123,931,289.91 from ¥164,405,947.02, a reduction of 24.5%[34] - The total liabilities amounted to ¥164,405,947.02, with current liabilities at ¥149,730,859.80[54] - The company reported a non-current liability of ¥14,675,087.22, which includes deferred income of ¥14,621,720.82[54] - The total equity attributable to shareholders of the parent company is ¥1,128,491,766.09[57] Cash Flow - The cash flow from operating activities for the year-to-date was ¥124,291,686.18, showing a decrease of 16.75% compared to the same period last year[6] - Cash inflow from operating activities totaled CNY 601.56 million, up from CNY 501.78 million, indicating a year-over-year increase of 19.9%[44] - Cash outflow from operating activities was CNY 477.27 million, compared to CNY 352.48 million in the previous period, resulting in a net cash flow from operating activities of CNY 124.29 million, down from CNY 149.30 million[44] - Investment activities generated a net cash outflow of CNY 75.96 million, an improvement from a net outflow of CNY 213.65 million in the previous period[44] - The company received CNY 5.25 million from financing activities, a decrease from CNY 72.80 million in the previous period[44] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,306, with the top 10 shareholders holding a combined 57.27%[16] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[16] - The number of shares held by the top 10 unrestricted shareholders includes Forward Investment (Hong Kong) Limited with 48,723,120 shares[16] - The company has a total of 2,123,700 restricted shares, all subject to unlocking according to the 2019 stock incentive plan[21] - The total number of restricted shares held by core management and technical personnel is 1,105,200, subject to unlocking regulations[21] - The company has not identified any related party relationships among the top shareholders, except for familial ties between certain partners[20] Operational Costs and Expenses - The company experienced a 70.09% increase in operating costs, totaling ¥103,791,219.27, mainly due to higher costs associated with multi-gene joint reagent products and increased testing service costs[12] - Total operating costs amounted to ¥457,191,133.58, up from ¥360,802,462.50, reflecting a year-over-year increase of 26.7%[36] - Research and development expenses were ¥109,167,134.77, which is a 26.2% increase compared to ¥86,512,568.40 from the same period last year[36] - The company's financial expenses increased by 112.83% to ¥2,284,183.71, primarily due to increased exchange losses[12] - The company reported a significant reduction in other payables, decreasing from ¥78,402,545.82 to ¥33,936,655.44, indicating improved financial management[31] Market Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[36] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[46] Other Financial Information - The company's cash and cash equivalents as of September 30, 2021, amount to ¥346,613,750.41, a decrease from ¥361,560,881.46 at the end of 2020[25] - Accounts receivable increased to ¥403,918,807.11 from ¥316,510,008.54 year-over-year[25] - Inventory has risen to ¥35,688,034.43, compared to ¥21,433,011.25 at the end of 2020[25] - The company reported a total asset value of CNY 1.29 billion, slightly down from CNY 1.29 billion in the previous period[51] - The total liabilities amounted to CNY 23.53 million, with accounts payable at CNY 14.04 million and contract liabilities at CNY 9.48 million[51] - The company has implemented new leasing standards starting from 2021, affecting prior comparative data[57] - The report indicates a capital reserve of ¥441,942,648.04 and a share capital of ¥221,808,000.00[54] - The company has a total of ¥78,402,545.82 in other payables, which includes employee compensation of ¥35,325,504.89[54] - The company reported a total of ¥2,050,135.96 in lease liabilities[54]